

## MYA CARYN SCHIESS, M.D.

### PRESENT TITLE AND POSITION

Professor of Neurology, Tenured  
 Adriana Blood Distinguished Chair in Neurology  
 Department of Neurology  
 Clinical Director, Movement Disorders/Neurodegenerative Diseases Clinic, (UT MOVE)  
 Program Director Movement Disorders Fellowship Training Program

### WORK ADDRESS

The University of Texas Medical School at Houston  
 Department of Neurology  
 6431 Fannin, MSB 7.108  
 Houston, Texas 77030  
 Telephone: 713- 500-7121  
 Fax : 713- 500-5055  
 Email: [mya.c.schiess@uth.tmc.edu](mailto:mya.c.schiess@uth.tmc.edu)

### LABORATORY

Blood & CSF analysis, bioassay and immune phenotyping  
 Cell Cultures, CSF analysis for protein and cytokines  
 Intracellular Electrophysiology/Neuropharmacology, HPLC  
 6431 Fannin, MSB 7.306  
 Houston, Texas 77030  
 713-500-7073

### CITIZENSHIP

United States of America

### UNDERGRADUATE EDUCATION

1969 - 1973 Bachelor of Arts, Double Major Experimental Psychology & Physiology  
 Phi Beta Kappa 1971, The University of California at Berkeley, Berkeley, California

### RESEARCH TRAINING

06/1975 -09/1975 Factors governing female menstrual cycles. The University of New Mexico, Departments of Psychology and Physiology, Sponsor Dennis Feeney, Ph.D.  
09/1975-01/1976 Research in Stereotaxic Neurosurgery including mapping the rat brain for self-stimulation with microelectrode implants. The University of New Mexico. Departments of Psychology and Physiology, sponsor Dennis Feeney, Ph.D.

<b>GRADUATE EDUCATION</b>	<u>1976- 1980</u>	Doctor of Medicine, The University of New Mexico, School of Medicine, Albuquerque, New Mexico. Alpha Omega Alpha (AOA) 1980
<b>MEDICAL SCHOOL RESEARCH ACTIVITIES</b>	<u>06/1977-09/1977</u>	Medical Student Research Program; NSF Student Research Grant: Development of Radioreceptor Assay for Somatostatin. The University of New Mexico School of Medicine Endocrine Laboratory, Albuquerque, New Mexico, Sponsor Glen Peake, M.D.
	<u>06/1978-09/1978</u>	Pharmacological studies of anterior pituitary hormone release and concentrations of GH, TRH, SRIF, and PR following morphine and naloxone in rats. The University of New Mexico School of Medicine Endocrine Laboratory, Albuquerque, New Mexico, Sponsor Glen Peake, M.D.
<b>POST GRADUATE TRAINING</b>	<u>1980- 1981</u>	Internship Internal Medicines Parkland Memorial Hospital and Veterans Administration Hospital, The University of Texas Health Science Center, Southwestern Medical School, Dallas, Texas. Donald W. Seldin M.D., Chairman
	<u>1981- 1984</u>	Residency Neurology Parkland Memorial Hospital and Veterans Administration Hospital, The University of Texas Health Science Center, Southwestern Medical School, Dallas, Texas. Roger N. Rosenberg, M.D., Chairman
	<u>1984- 1990</u>	Fellowship NIH K11, Neurophysiology /Pharmacology Research The University of Texas Southwestern Medical School, Dallas, Texas, Department of Physiology Faculty Supervisor Robert Moss, Ph.D. 1984-1986
	<u>1986- 1990</u>	Fellowship NIH K11, Neurophysiology /Pharmacology Research The University of Texas Medical Branch-Galveston, Texas, Department of Pharmacology, Faculty Sponsor Patricia Gallagher, Ph.D.
<b>ACADEMIC APPOINTMENTS</b>	<u>1984- 1986</u>	Instructor of Physiology and Neurology Department of Physiology, The University of Texas Southwestern Medical School, Dallas, Texas NIH K11
	<u>1986- 1990</u>	Instructor of Pharmacology and Neurology Department of Pharmacology and Toxicology, The University of Texas Medical Branch-Galveston (UTMB) Texas, NIH K11
	<u>1990- 1999</u>	Assistant Professor, Department of Neurology, and secondary Appointment in the Department of Pharmacology and Toxicology UTMB, Chair John Calverley, MD
	<u>1999- 2001</u>	Assistant Professor of Neurology Department of Neurology, The University of Texas Houston Medical School (UTHMS), Houston, Texas, Neurology. Chair James Ferrendelli, MD
	<u>2001- 2006</u>	Associate Professor of Neurology

Department of Neurology, UTHMS. Chair James Ferrendelli, MD

2007- Present Professor of Neurology  
Department of Neurology, Neurology Chair James Grotta, MD

2012- Present Tenured Professor of Neurology  
Department of Neurology, Chair James Grotta, MD

2001- Present *Director of Movement Disorders Fellowship Training Program  
UT Health Science Center-Houston*

2001- Present Clinical Director of Movement Disorders and Neurodegenerative Diseases  
Clinics, UTP Clinics

2001- Present *UT MOVE, Clinical Director*

Unique and nationally recognized subdivision of clinical expertise in the  
Department of Neurology at UTHMS.

Purpose: UT MOVE clinic program offers focused attention on the  
neurological conditions of motor systems disruption, including the  
movement disorders, cerebral palsy, spasticity, the neurodegenerative  
diseases, and dementias. It incorporates both an adult, geriatric and  
pediatric population, with expert faculty in each area. The faculty and  
participants in this program offer expertise in diagnosis, management, and  
medical and surgical therapeutic interventions for the specific disease  
states. The UT MOVE clinic serves the greater Houston community and is a  
referral center for the entire state of Texas and surrounding states.

*Key Activities:*

\*Developed the only neurology directed Spasticity Management Clinic and  
currently have the largest Intrathecal Baclofen (ITB) pump population  
selected and managed by Neurology in the USA.

\*Developed an active surgical program for Deep Brain Stimulation for  
Parkinson's disease, Dystonia, and Tremor.

\*Developed the Botulinum Toxin Injection clinic for focal Dystonias, focal  
spasticity, and headache management

2001- 2009 Director of Movement Disorder Clinic for LBJ HCHD Hospital  
Provide specialty neurological care to patients with Parkinsonism, spasticity,  
tremors, dystonia, and other movement disorders. Two clinics per month  
that provide subspecialty patient care. Average 12-15 patients per clinic.

2002- 2009 Director of the Neurology Residency Training Program

2007- 2012 Adriana Blood Endowed Chair in Neurology

2009- 2016 Vice Chair of Neurology

2012- Present *Adriana Blood Distinguished Chair in Neurology*

#### ADMINISTRATIVE AND CLINICAL POSITIONS

#### EXTRA- DEPARTMENTAL AFFILIATIONS, RESPONSIBILITIES

2009- Present Teaching faculty for Sleep Medicine Fellowship  
2010- 2011 CORE TEACHING FACULTY FOR NEUROLOGY

**HOSPITAL  
APPOINTMENTS**Full Active Privileges

1980-1987	Dallas County Parkland Hospital, Dallas, Texas
1980-1987	Veteran's Affairs Hospital, Dallas, Texas
1987-1999	John Sealy Hospital, Galveston, Texas
1999-Present	Memorial Hermann Hospital, Houston, Texas
1999-Present	Texas Institute of Rehabilitation and Research, Houston, Texas
1999-Present	Lyndon B. Johnson General Hospital, Houston, Texas
2002-2008	St. Luke's Episcopal Hospital, Houston, Texas
2005-2008	Methodist Hospital, Houston, Texas

Consultant Privileges

1995-2005	MHMR Richmond State School, Richmond, Texas
-----------	---

**LICENSURE**

Texas Medical License G7427

**CERTIFICATION**

\*American Board of Psychiatry & Neurology Membership 48016 Issued: 1995

\*Recertified in 2004 and MOC Renewal

\*Recertified in 2014 and MOC Renewal

\*Texas Department of Public Safety Certificate T0061774

\*Drug Enforcement Agency Certificate AS3107186

\*ACLS Certificate

**PROFESSIONAL  
ORGANIZATIONS**Local:

1992- Present	Texas Medical Association
1998- Present	Texas Neurological Society
2000- Present	Houston Area Parkinson's Society
2009- Present	Houston Neurological Society
2010- Present	National Ataxia Foundation (Local Chapter)

National

1971- Present	Phi Beta Kappa Chapter Member
1976- Present	Alpha Omega National Society Member
1982- Present	American Medical Association
1986- Present	Society for Neuroscience
1987- Present	The New York Academy of Sciences
1993- Present	American Academy of Neurology
1998 -Present	Movement Disorder Society
1999- Present	National Stroke Association
1999 -Present	International Essential Tremor Foundation
2000- Present	National Parkinson's Foundation
2002- Present	Parkinson's Study Group
2012- Present	Fellow of the American Neurological Association

<b>HONORS AND AWARDS</b>	1971	Phi Beta Kappa from the University of California, Berkeley
	1980	Alpha Omega Alpha from the University of New Mexico Medical School
	1984	Physician Scientist Award (K-11) NICHHD
	1999-2015	“Dean’s Excellence in Teaching Award”, The University of Texas Medical School at Houston.
	2008-Present	Selected by peers to Tx Top Docs list as published in Texas Monthly
	2008 -Present	Selected by peers to Super Doctors list as published in Texas Monthly
	2007	Houston Area Parkinson Society Annual Awards-Joint Recipient of Roy H. Cullen Quality of Life Award given to HAPS Medical Advisory Committee
	2007- 2012	Adriana Blood Endowed Chair in Neurology in recognition and support for Vice Chair responsibilities, leadership, and as Director of Movement Disorders Research Program and research projects.
<b>EDITORIAL POSITIONS AND REVIEWER</b>	2012-Present	Adriana Blood Distinguished Chair in Neurology in recognition and support for Vice Chair responsibilities, leadership, and as Director of Movement Disorders Research Program and research projects.
	2017	Academy of Master Educators Membership. UTHealth
	2000- 2008	Reviewer, <i>Archives of Neurology</i>
<b>SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS</b>	2004- Present	Reviewer, American College of Physicians
	2005- Present	Reviewer, <i>Trends in Pharmacological Sciences</i>
	2017- Present	<i>Ad hoc reviewer</i> Reviewer <i>JNNP, BMJ Neuroscience</i>
	2008- Present	Editorial Board, ( <i>Archives of Neurology</i> ) <i>JAMA Neurology</i>
<b>SERVICE ON McGovern</b>	<u>1999- 2011</u>	Reviewer for the University of Texas at Houston Department of Neurology “Young Investigator Award”
	<u>1999- 2015</u>	National Student Research Forum Grant Reviews for the National Science Foundation Manuscript and Abstract Reviews for annual meetings
	<u>2003- 2009</u>	Continuing Medical Education Committee for the Association of University Professors in Neurology.
	<u>2008- Pres ent</u>	Neurology Residency Program Directors Focus Group- Develop curriculum for teaching DBS therapies to Neurology residents. Develop Curriculum for teaching Movement Disorders to Neurology Residents.
	<u>2011- Pres ent</u>	Reviewer for the University of Texas Center Clinical & Translational Sciences “KL2 program Award”
	<u>2013- P res ent</u>	Abstract Reviewer for American Neurological Association Annual Meeting.
<b>SERVICE ON McGovern</b>	2002	Liaison Committee on Medical Education Clinical Departments/GME/CME

<b>MEDICAL SCHOOL COMMITTEES</b>	2002- 2012	Curriculum Committee, Medical School
	2004	Search Committee for a Director of Neurosciences Institute of Molecular Medicine
	2009	Search Committee for Chair of PM&R
	2000, 2006, 2009	Committee on Committees
	2010-Present	Faculty Senate
	2010-2011	Chair-Elect, Faculty Senate
	2011-2012	Chair, Faculty Senate
	2012-2015	Faculty Senator for Neurology Chair – Committee to Update UTMSH Bylaws
	2012-2013	Interfaculty Council committee member for Medical School
	2012-2015	Faculty Appointments, Promotions and Tenure Committee
	2012-Present	Education Committee for Neurology
	2014-2015	Search Committee for the Chair of Neurology
	2015-2018	Faculty Senator for Neurology
	2015-2018	Faculty Appointments, Promotions and Tenure Committee
	2017	Committee to re-write guidelines “Promotion Non-Tenure Clinical Track “

<b>SERVICE ON COMMITTEE FOR THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON</b>	<u>1993 - 1999</u>	Pharmacy and Therapeutics Committee Active/Voting member, Developed “Guidelines for the Management of Vascular Headaches”, Developed “Guidelines for the Management of Seizure Disorders.”
	<u>1994- 1999</u>	Appointed member of Texas Department of Criminal Justice Formulary Committee
	<u>1995 - 1999</u>	Member of Neurology CME Accreditation Committee

<b>SERVICE ON GRADUATE SCHOOL COMMITTEES</b>	<u>The University of Texas Health Science Center at Houston :</u>	
	1999 – Present	Neuroscience Research Center Member
	2000 –2012	The University of Texas Health Science Center at Houston Graduate Medical Education Committee
	2003 –2009	Graduate Medical Education Internal Review Executive Committee
	2004–Present	Member of The University of Texas Graduate School of Biomedical Sciences at Houston
<u>The University of Texas Medical Branch at Galveston :</u>		
1994 – 1995	Active members of the Integrated Learning Tract alternative curriculum committee for review and implementation of cases for the Case-Based Learning Integrative Learning Tract.	

	1995 – 1999	Member of Neurology Curriculum Committee for the Neurology Residency Three Year Academic Program (including weekly teaching sessions).
<b>SERVICE TO THE COMMUNITY</b>	1987 – 1999	Volunteer Physician Work at St. Vincent’s House Free Medical Clinic, Galveston, Texas
	1995 –2005	Neurology consultant: Richmond State School MHMR Facility Richmond, Texas
	2003- 2006	Subspecialty Movement Disorders Clinic at LBJ County Hospital Monthly- referred patients from all County Hospitals and Clinics
	2004 - Present	Developed and presented in both, half days, summer lectures and annual educational symposium to patients and family for Houston Area Parkinson’s Society (HAPS). Presentations over the years include “Early Parkinson’s Disease – an Overview of Disease and Management”, “Non-motor Symptoms of PD”, “Parkinson’s disease Clinical Trials and Research Update”, “Sleep disorders in PD”, “Surgical Interventions for PD”, “Update on DBS Therapy for PD”, “Prodromal Parkinson’s Disease: an overview of pre-clinical symptoms and molecular markers”, “ Newly Diagnosed Parkinson’s Disease: Diagnosis, Epidemiology, Natural History and Effective Therapies, Motor and non-Motor symptoms”, “Beyond Shaking and Slowness: understanding the other symptoms of PD” “Supplements in PD”.
	2006- Present	Houston Area Parkinson Society Member Medical Advisory Committee. Two half-day Saturday Seminars to the Newly Diagnosed Parkinson ’s disease patient and their partners, support/friends. Spring and Fall series “Newly diagnosed Parkinson’s disease Educational Seminar.”
	8/2010	National Ataxia Foundation Local chapter Annual Symposium Organized and created Half-day Seminar on Ataxias, Update on diagnosis, therapies and research Speakers: Mya Schiess, MD, Brian Aalbers, DO
	2/2013	HGEC “Demystifying Dementia- Improving Diagnostic Accuracy”; Presented “Dementia with Lewy Bodies”; February 23, 2013, Half-day symposium at Amazing Place, Houston, Texas
<b>POSTGRADUATE TEACHING AND EDUCATIONAL PROGRAMS - ADMINISTRATIVE</b>	<u>1999- 2009</u>	Director of Education for Neurology Residents Training Coordinated and scheduled the daily noon didactic lectures to Neurology Residents
	<u>2002- 2009</u>	Director of Neurology Residency Training <i>Accomplishments:</i> RRC/ACGME Site Visit: April 2003 Established A+ rating and 5 years accreditation with no citations. Wrote the first Program Information Form (PIF) for our Neurology Program. RRC/ACGME Site Visit: March 2009 Successful full accreditation for 3 years with No citations. <i>Duties and Responsibilities:</i>
<i>Mya Schiess, MD</i>		

Arrange the Rotation Schedules for the Residents in compliance with ACGME requirements for successful completion of all residency requirements for each resident.

- Created the UT Neurology Residency Training Handbook 2001, edited yearly through 2009
- Created Core Competency Assessment Tools
- Created the Evaluation tools for Residents and Faculty
- Created Goals and Objectives for Residency Training for all Rotations
- Created and Formulated All Policies for UT Neurology Resident Training

2007- 2009

Created a separate Neurology Residency Educational Syllabus and Handbook. Created the internal structure for the five NEX Clinical Exams required for advancing to board eligibility and replacing the Part II oral boards in Neurology.

2008- Pre sent

Course Director MS4 Movement Disorders Rotation – One Month Elective  
Created and Director for this one-month elective rotation in our movement disorders program and clinics. This has been a very successful rotation that has filled every month since initiation and exposed the MS4 to the outpatient specialist clinic. This rotation requires the fourth year Medical Student to 1) learn the approach to tremor, dystonia, parkinsonism, all abnormal movements and cognitive impairment disorders; the criteria for diagnosis and management principles 2) experience the Botox injection clinic, intrathecal baclofen spasticity clinic, DBS selection and programming, as well as microelectrode intraoperative recording for DBS 3) experience clinical research protocols by observing the ongoing trials.

2009- 2014

Faculty Preceptor for Physical Diagnosis Course for second-year Medical Students (MS II).

2016- present

Developed the didactic program, curriculum, and structure with Dr. Raja Mahanna as co-Director for teaching Neurology Residents rotating in the Movement Disorders specialty clinic. Educational materials include faculty seminars, reading material from the *Continuum* and selected articles; Learning objectives and a written exam based on RITE exam questions and AAN core knowledge requirements.

**SPONSORSHIP OF  
CANDIDATES FOR  
POSTGRADUATE  
DEGREE**

1995- 1997

Eva Ma, M.D., Ph.D. Clinical Advisor UTMB

2001- 2003

Ashley Cain, BS. Masters Theses Committee for Masters Degree

2004-2009

Ashley Jagar Hood, Ph.D. Doctoral Thesis Committee

Academic Advisory Committee for Neuroscience Pre-Doctoral candidate.

2005-2006

Supervisory Committees for Ph.D. Thesis.

Co-Director/Sponsor for Doctoral Graduate Student, Ruth L. Kirschstein

National Research Service Award Individual Fellowship, "Deep Brain



<u>2012 - 2015</u>	Stimulation & Attention in Parkinson Disease” Depts. Of Neurobiology/Neuroanatomy and Neurology, UTHSC Stuart D. Red, BA Doctoral Thesis Committee and Thesis Defense and Committee Approval for Awarding Ph.D. in Neurosciences, Department of Neurobiology and Anatomy.
<u>2013- 2015</u>	Clinical Research Mentor for K12 recipient: Dr. Sheng Lou, Assistant Professor School of Public Health, “Innovative Statistical Methods for Analyzing Parkinson’s Disease Study Data”.
<u>2017- Pre sent</u>	Supervisor and Faculty Mentor for Postdoctoral Research Fellow, Dr. Jessika Suescun, MD, Department of Neurology, Movement Disorders Division

\* Mo ve m e nt Di so rd e rs Fe ll ow cu rre ntly h o ld s a n a ca d e m ic p o s i t i o n

- Ali Alrefai, M.D. 2001-2002 Movement Disorder Fellow.  
Current Position: Private practice in St Francis, WI. Affiliated with Aurora St Lukes Medical Center, Aurora St Lukes South Shore, and Aurora West Allis Medical Center
- \*Jerome Lisk, M.D. 2002-2003 Movement Disorder Fellow.  
Current Position: Director of Movement Disorders Christus Trinity Mother Frances Neuroscience Center and Assistant Clinical Professor at the University of Texas Northeast in Tyler, TX.
- Robert Izor, M.D. 2003-2004 Movement Disorder Fellow.  
Current Position: Private practice in Austin, TX. Affiliated with St. David's Round Rock Medical Center, St. David's Medical Center, St. David's South Austin Medical Center and St. David's North Austin Medical Center.
- \*Stanley Fisher, M.D. 2004-2005 Movement Disorder Fellow.  
Current Position: Co-Director of The Saint Luke's Marion Bloch Neuroscience Institute, Full professor at the University of Missouri Kansas City School of Medicine in Kansas City, MO
- Fernando Acosta, M.D. 2005-2006 Movement Disorder Fellow.  
Current Position: Associate medical director of movement disorders group at Cook Children’s Hospital in Ft. Worth, TX.
- \*Erin Furr-Stimming, M.D. 2006-2007 Movement Disorder Fellow.  
Current Position: Associate Professor at McGovern medical school part of UTHealth, Chief of Neurology Service at Lyndon B Johnson General Hospital in Houston, TX
- Irene Oh, M.D. 2007-2009 Movement Disorder Fellow.  
Current Position: Private practice in Carlsbad, CA. Affiliated with Palomar Medical Center Poway, Tri - City Medical Center, Scripps Memorial Hospital Encinitas and Palomar Medical Center Downtown Escondido.
- \*Anita Madan, MD 2008-2010 Movement Disorder Fellow.  
Current Position: Private practice in Toronto, Ontario. Assistive Technology Clinic
- Toby Yaltho, MD 2008-2009 Movement Disorder Fellow.  
Current Position: Private practice in Sugar Land, TX. Affiliated with Methodist Sugar Land Hospital.
- \*B. Glenn Kidder, MD 2009-2010 Movement Disorder Fellow, UTHMS

**SPONSORSHIP OF  
MOVEMENT  
DISORDERS  
FELLOWS**

Current Position: Private Practice Baton Rouge, LA. Affiliated with Our Lady Of The Lake Regional Medical Center, The Spine Hospital Of Louisiana, Baton Rouge General Medical Center, Lane Regional Medical Center.

- \*Katie Hendley, MD 2010-2011 Movement Disorder Fellow.  
Current Position: Private practice Lubbock, TX. Affiliated with University Medical Center and Covenant Medical Center. Assistant Professor at Texas Tech University Health Sciences Center.
- Brian Aalbers, DO 2010-2011 Movement Disorder Fellow.  
Current Position: Assistant Professor at UMKC School of Medicine, Kansas City, MO. Affiliated with Cook Children's Medical Center.
- \*Qinghua Liang, MD, Ph.D. 2011-2012 Movement Disorders Fellow.  
Current Position: Private Practice in San Antonio, TX. Affiliated with South Texas Veterans Health Care System, Medical Center Of The Rockies and Poudre Valley Hospital. Adjunct Assistant Professor at The University of Texas Health Science Center at San Antonio.
- \*Lalitha Guthikonda, MD 2012-2013 Movement Disorders Fellow.  
Current Position: Assistant Professor at McGovern medical school part of the University of Texas, Houston, TX.
- \*Brian Copeland, MD 2011-2013 Movement Disorders Fellow.  
Current Position: Assistant Professor and Director of the Neurology Residency Program at LSU, New Orleans, LA.
- \*Allison Boyle, MD 2013-2014 Movement Disorders Fellow.  
Current Position: Assistant Professor at McGovern medical school part of the University of Texas, Houston, TX.
- \*Michael Soileau, MD 2013-2014 Movement Disorders Fellow.  
Current Position: Director of the movement disorder center at Scott and White Healthcare, Temple, TX. Affiliated with St. David's Round Rock Medical Center. Assistant professor at Texas A&M health science center at Temple.
- \*Nivedita Thakur, MD, 2013-2014 Movement Disorders Fellow, Pediatric Neurology.  
Current Position: Assistant Professor at McGovern medical school part of the University of Texas, Houston, TX.
- Satish Gaddam, MD, 2014-2015 Movement Disorders Fellow.  
Current Position: Private practice in Fort Smith, AR. Affiliated with Sparks Regional Medical Center.
- \*Sara Hoque, MD, 2014-2016 Movement Disorders Fellow.  
Current Position: Currently on family leave
- Kamal R. Shah, MD., 2015-2017 Movement Disorders Fellow.  
Current Position: Addiction medicine Fellow at McGovern medical school part of the University of Texas, Houston, TX.
- \*Shivika Chandra, MD 2017-2018. Current fellow; future Harris Health and UTHSC faculty
- Valentin Laticevski, MD 2017-2018. Current fellow; future MDS practice in Seattle, WA.

**UT MOVE  
FELLOWSHIP  
PROGRAM  
ACCREDITATION**

2007-2012

Accredited the Movement Disorders Fellowship training program with the Texas State Medical Board Health Education Commission. Two years accredited fellowship for two postgraduates per year.

2012-2017	Re-accredited the Movement Disorders Fellowship Training program with the Texas State Medical Board Health Education Commission. Two-year program with clinical certification for the first year; approved for 2 fellows per year for two years.
<b>2017-2022</b>	<b>Re-accreditation for the Movement Disorders Fellowship Training Program with the Texas State Medical Board Health Education Commission. Two-year program with clinical certification for the first year.</b>
2012-Present	UT MOVE, our fellowship program joined the SF Match for fellowship positions in Movement Disorders; National Matching organization.

### TEACHING AND TRAINING DISTINCTIONS FOR UT MOVE

- Designated Regional/National Training Site for DBS selection and programming
- Invited and joined the Parkinson Study Group May 2005. The Parkinson's Study Group (PSG) is a consortium of selected professional and academic research centers. The PSG facilitates and sponsors the development of investigator-initiated research in Parkinson's disease.
- Designated Regional /National Training Site for ITB selection, trials, refills, and programming
- **Designated 2017- top 10 (#9) DBS implanting centers in the USA.; Community Centric DBS Implanting and Programming Center/Clinic at UT MOVE.**

### SUPERVISORY RESPONSIBILITIES AND TEACHING ACTIVITIES FOR UT MOVE

- Five half-day clinics per week at UTP/TMC.
- Supervision and teaching of Residents/Medical Students/Fellows rotating thru clinics
- Supervision and teaching of Movement Disorder Fellow
- Three half- days per week- Conducting and teaching with clinical trials on identifying Biomarkers for the presymptomatic diagnosis of Parkinsonism. Rating Scales and Classification Schema; outcomes research in medical and surgical management for subtypes of Parkinson's disease. Video-taping/Rating Scales and pre-operative evaluation for Deep Brain Stimulation (DBS) procedures; DBS programming and post-operative follow up video and rating scales.
- Development of UT MOVE clinic at the Woodlands Memorial Hermann Hospital.  
Two full day clinics per month since August 2013-2016.  
This is the first subspecialty clinic in the Woodlands, Spring, Kingwood, Humble area to provide expert clinical and procedural services to our patient population including DBS programming, ITB pump refills and adjustments and botulinum toxin injections and medical management and diagnosis.

### Annually 2007 – Present

Two, one-hour lectures per month, updated annually and repeated every year. Audience: neurology residents, fellows, and rotators.

### UT MOVE LECTURE SERIES FOR MOVEMENT DISORDERS &

July	Emergency Management lectures- Urgent Hypokinetic Movement Disorders Urgent Hyperkinetic Movement Disorders
------	--

**NEURODEGENERATIVE DISEASES**

August	Idiopathic Parkinson's disease Part I and Idiopathic Parkinson's disease Part II
September	Essential and Other Tremors, DBS Therapies for Parkinson's disease, Tremor, and Dystonia
October	Generalized Dystonia/DYT1-13, Focal Dystonia
November	Botulinum Toxin-Basic Science and mechanism of Action, Botulinum Toxin Injection Therapy for Focal Dystonia, Cervical Dystonia, Writers' Cramp, Hemifacial Spasm Blepharospasm, Hyperhidrosis, Sialorrhea, Headache
December	Abnormal Tone-Spasticity & Rigidity, Spasticity Management – Botox Injections & ITB Therapy
January	Multiple System Atrophy and Diffuse Lewy Body Disease
February	Ataxia – Spinocerebellar Diseases and Dyskinesias - Drug & Paroxysmal
March	Sleep Disorders, REM sleep Behavior Disorder, Restless Leg Syndrome Chorea/Huntington's Disease/HDL 1 & 2
April	Myoclonus/Focal/Segmental/Myoclonus – Dystonia Syndrome Wilson's disease, Copper Dysmetabolism
May	Progressive Supranuclear Palsy and Corticobasal Degeneration
June	PD Biomarkers Clinical Trial Update and Neuroimaging in Movement Disorders

**MEDICAL STUDENT, RESIDENT/FELLOW, AND GRADUATE STUDENTS LECTURES**

<u>02/19 99</u>	Neurobiology of Disease Course- Description of Movement Disorders; Pathophysiology of Extrapyrmidal Movement Disorders; Medical Treatment of PD and Related Disorders
<u>02/200 1</u>	PBL Case Writer for Multiple Sclerosis Exam Case and Pernicious Anemia/Subacute Combined Degeneration of the Spinal Cord
<u>2002- 2005</u>	UTSMH Master Teacher Teaching Residents How to Teach –included 21 cases based vignettes for Clinical Neurology Training
<u>2003- 2005</u>	UTHMS Medical Student Teaching: Clinical Correlates in Upper Motor neuron dysfunction - MSI class Clinical Correlates in Ataxia - MSI class Neurodegenerative Diseases - MSII class
<u>2004- 2005</u>	PBL Case Rewrite for Clem Johnson – Parkinson's disease November Neuroscience section
<u>10/200 5</u>	Principals-Disorders of the Nervous System in Principles of Pathology Histopathological Basis for Disease. Pathology Dept. Graduate students UTHMS
<u>09/200 7</u>	Neurobiology of Disease - Non-Alzheimer's Dementias
<u>10/201 1</u>	Neurobiology of Disease – Restorative Potential in PD
<u>2000- 2015</u>	Core Lectures in Movement Disorders for Internal Medicine Residents – American Board Core lecture and MKSAP
<b><u>2009- Pre sent</u></b>	Neurological Exam for MS4 2 hour March/Match Reviews

	March Required Transition to Residency Month.
	WORKSHOP "Neurologic Exam for the Intern" Dr. Schiess
<u>11/2016</u>	Neurobiology of Disease, GSBS "disease, Role of neuroinflammation Neuroinflammation in PD and MSA"
<u>7/2018</u>	Neurobiology of Disease, GSBS "Oligomerized alpha-synuclein strains and levels in Parkinson's disease: body fluid comparisons and clinical significance" Mya Schiess, MD and Claudio Soto, Ph.D.
<u>01/2005</u>	Tau protein, $\alpha$ -synuclein, glial cytoplasmic inclusions and Atypical Parkinsonian Disorders
<u>08/2005</u>	Clinical Pathological Conference: Encephalomyelitis
<u>04/2006</u>	Tau, $\alpha$ -synuclein and Glial Cytoplasmic Inclusions
<u>07/2007</u>	Management of Abnormal Tone
<u>10/2007</u>	DYT1 and other Dystonias: DBS Therapy
<u>11/2008</u>	Adult Spasticity Management: Case Presentation and Review of Intrathecal Baclofen Therapy
<u>02/2009</u>	Movement Disorders for Department of Physical Medicine and Rehabilitation
<u>03/2009</u>	PD Therapies for Department of Psychiatry
<u>05/2009</u>	CPC: Neuroleptic Malignant Syndrome
<u>11/2009</u>	Parkinson Disease: a Neuroinflammatory Process
<u>12/2009</u>	Fluid and Imaging Biomarkers in Parkinson's disease
<u>04/2010</u>	PD Update on Research and New Therapies
<u>11/2010</u>	Movement Disorders Review for Department of Internal Medicine
<u>10/2011</u>	Restorative Potential in Parkinson's disease: Gene-based and cell-based therapies; Neurobiology of Disease Fall Seminars
<u>03/2012</u>	Diffusion Tensor Imaging correlates of STN Deep Brain Stimulation efficacy in tremor-dominant Parkinson's disease
<u>11/2012</u>	REM Sleep Behavior disorder as prognostic for Parkinsonism
<u>12/2015</u>	Neurodegeneration- Alpha-synucleinopathies: GSBS Molecular Pathology Series.
<u>05/2015</u>	"Essential and other Tremors" given to the Internal Medicine Residents and Fellows as part of their Neurology Lecture Series
<u>06/2015</u>	"Parkinsonism and Parkinsonian Disorders" given to the Internal Medicine Residents and Fellows as part of their Neurology Lecture Series
<u>09/2015</u>	"Parkinson's Disease: an update" Family Medicine faculty, residents, and fellows in Neurology Lecture Series.
<u>04/2016</u>	Mesenchymal Stem cells in the Treatment of Parkinson's Disease, Neurology Grand Rounds
<u>05/2017</u>	"Targeting the dentato-rubral-thalamic tract with DBS for tremor control." Shivika Chandra, MD and Mya Schiess, MD, Neurology Grand Rounds

**NEUROLOGY  
DEPARTMENT  
GRAND ROUNDS  
OR EXTRA-  
DEPARTMENTAL  
INVITED LECTURES  
AT UT HEALTH**

**Local / Regional:**

	04/1996	Stroke- what it can mean to you and your family MPS Media Production- Lecture to Community in Levine Hall, Galveston, Texas
	04/1996	Update on Research, Therapy, and Legislation Functional Outcome of Image Intensive Pallidotomy Surgery Seminar Houston Area Parkinson Society- Sixth Annual Symposium City of Houston Multi-Service Center, Houston, Texas
	05/1996	Emergency Management of Adult Seizures and Strokes- What to do in the Pre-hospital Setting, Rural Emergency Education Network Telecommunications (RECENT), Houston, Texas
	11/1996	Parkinson's Disease Medstar Channel 11 Television Series, Houston, Texas
	03/2000	Parkinson's disease: Update on Medical Interventions, Neurology Update, Houston, Texas.
	06/2000	COMT Strategies for the Parkinson's patient- Case Studies Houston Clinical Forum- sponsored by Novartis, Houston, Texas
	03/2001	Postural Instability, Parkinson Foundation of Harris County invited lecture, Houston, Texas
	09/2002	New Therapies for Movement Disorders; DBS, ITB, and BOTOX. Houston, Texas.
	10/2002	Introduction to Movement Disorders TIRR and Combined UT/Baylor PM&R Residents: Houston, Texas.
<b>PRESENTATIONS/ INVITED LECTURES OR SEMINARS</b>	01/2003	Brain/Mind Function; what goes wrong in PSP, Progressive Supranuclear Palsy Houston Society Lecture, Houston, Texas
	04/2003	Case Studies of Keppra (levetiracetam) use in the Developmentally Disabled Population, Annual MHMR/APDDA conference, Austin, Texas.
	06/2003	Parkinson Disease- Definition, Diagnosis, New Treatment Options. CME Seminar for TIRR Nurse Case Managers and Social Workers Marriott Medical Center, Houston, Texas.
	11/2003	Patient Selection Process for Deep Brain Stimulation Medtronic Incorporated Symposium: Lecturers: Dr. Schiess, Dr. Tintner, and Dr. Simpson, Marriott Medical Center Hotel, Houston, Texas
	02/2004	Willowbrook Methodist Hospital Deep Brain Stimulation in the Treatment of Parkinson's Disease: Young Onset Parkinson's Disease. HAPS Houston Area Parkinson's Society, Houston, Texas
	02/2004	Intrathecal Baclofen for the treatment of Spastic Hemiplegia Due to Stroke, Channel 11 News, Houston, Texas
	09/2004	Parkinsonism and Manganese Exposure Welders at Risk: Channel 11 / CBS affiliate, Houston, Texas
	09/2005	Parkinson's disease treatment has changed: Medication options, surgical options, and future options. PR Community Education Campaign sponsored by Medtronic Inc., Houston, Texas.

- 06/2005 Applications of Botulinum Toxin in contemporary Neurologic and Psychiatrist Practice. Instructional Workshop arranged in cooperation with Physical Medicine and Rehabilitation Alliance of the Baylor College of Medicine and The University of Texas Houston Health Science Center, Houston, Texas.
- 09/2005 Houston Press Over stimulated How taking a Parkinson's disease wonder drug apparently makes some people want to gamble and have sex all the time By Todd Speak Published: Thursday, September 15, Houston Press
- 09/2005 Pasadena Citizen Procedure helps man combat Parkinson's disease. By: Jennifer Branch, Citizen reporter, Pasadena Citizen (circ: 17,175).
- 09/2005 An update in treating Parkinson's disease essential tremor, spasticity, and dystonia. Medtronic, Inc., San Antonio, Texas.
- 02/2006 ITB Therapy in the Stroke Population, Dallas Community Dinner Seminar, Dallas, Texas
- 02/2006 ITB Therapy for Spasticity Management in the Stroke Population, Baylor PM&R Grand Rounds, Dallas, Texas
- 02/ 2007 Texas Neurological Society meeting Invited Speaker for Clinical Update in Parkinson's Disease Austin, Texas
- 06/2008 Gulf Coast PA Society- Dopamine Management Theory: How Azilect can be used as Monotherapy or Adjunct Therapy in Parkinson disease.
- 01/2009 Overview of Essential Tremor: Medical and Surgical Treatment Options Katy, TX, ET Support Group
- 03/2009 Movement Disorders: PD Diagnosis and Treatment Psychiatry Residency Training Program, HCPC.
- 04/2009 Community Information Sharing, Seminar on Parkinson's Science: Innovations and New Perspectives, sponsored by HAPS and NPF; Houston, Texas
- 07/2009 Non-motor symptoms in PD- recognition and management" Houston Area Chapter for National Parkinson's Foundation, community lectures.
- 08/2009 DBS Dystonia Task Force Overview of Dystonia Treatments, Cook Children's, Ft. Worth, TX
- 05/2010 MNI Neuroscience Update: DBS Therapy in PD: Who benefits and for how long?
- 07/2010 Texas Neurological Society Botulinum Toxin Injection Therapy, San Antonio, TX.
- 08/2010 3<sup>rd</sup> Annual DBS Dystonia Task Force, Cook Children's, Ft. Worth, TX
- 06/2011 Treatment Initiation in Parkinson's Disease for Houston Area Nurse Practitioners Educational Seminar
- 03/2011 Rice University Neurocognitive Graduate Students Journal Club, Neurocognitive Impairment in Parkinson's Neurodegeneration
- 08/2011 RBD in Neurodegenerative diseases; Houston Movement Disorders Journal Club.
- 03/2012 1<sup>st</sup> New Horizon's NeuroSymposium in Lubbock, Texas "Parkinson's disease Update " March 10<sup>th</sup>, 2012

- 03/2012 Keynote Speaker for the 3<sup>rd</sup> Annual Parkinson's disease Conference DEFEAT PARKINSONS, Organization & Texas Home Health, "How to Cope with Non-Motor Symptoms of Parkinson's", Nacogdoches, TX.
- 04/2012 "Living Well with Parkinson's disease", Keynote Speaker for Lubbock Annual Parkinson's Disease Support Group, Lubbock, Texas
- 04/2012 "Advances in Science: Clinical Trials and Research Updates" for HAPS Annual Support Group Symposium, United Way, Houston, Texas
- 06/2012 Multimodal Integration: Integrating Intracranial Electrodes and Diffusion Tractography to Study Resting State Networks, Case Study: Single Subject and Group Analysis, University of Texas.
- 8/2012 Targeted Drug Delivery for Pain and Neurological Conditions Conference, sponsored by Neurovations Invited Speaker " Role of Intrathecal Baclofen Therapy on Post Stroke Recovery", Houston, Texas
- 02/2013 Demystifying Dementia- Improving Diagnostic Accuracy Houston Geriatric Education Center Invited Speaker "Dementia with Lewy Bodies", Amazing Place, Houston Texas.
- 05/2014 House Calls- Stem Cell Therapy in Neurological Disorders  
Sponsored by Dr. and Mrs. Dannenbaum for UT Development
- 03/2015 Hope Clinic- Community Health Care Clinic, Houston, Texas- Seminar on Parkinson's Clinical Trials and Patient Participation; developed for the Recruit Study for Minority Recruitment; Jessika Suescun and Mya Schiess
- 07/2015 "Parkinson's Disease: an update and introduction to participating in clinical research trails": developed for the Recruit Study for minority recruitment, given by Mya Schiess and Jessika Suescun to the Chinese Community Center at the Chinese Baptist Church, Houston, Texas.
- 03/2016 Rehabilitation Solutions 2016 Agenda "Medical And Surgical Advances in Parkinson's Disease Therapies" Memorial Hermann/TIRR Annual Symposium
- 04/2016 "Treating Parkinson's disease" on Great Day Houston show host by Deborah Duncan on Channel 11.
- 04/2016 Seminar on the "Latest Updates in the treatment of Parkinson's disease and Essential Tremor: Deep Brain Stimulation therapy". Mya Schiess, MD and Albert Fenoy, MD at Cooley Conference Center, Houston, Texas.
- 05/2016 MNI/MH Webinar on Parkinson's disease diagnosis and treatment with an emphasis on Deep Brain Stimulation; available on demand through MNI/UTHealth/McGovern Medical School website.
- 05/2016 MNI/MH Webinar on Essential Tremor diagnosis and treatment with an emphasis on Deep Brain Stimulation; available on demand through MNI/UTHealth/McGovern Medical School website.
- 09/2016 "Advancing clinical practice in neurodegenerative disease rehabilitation" Memorial Hermann/TIRR Annual Symposium.
- 01/2017 PSP Network of Houston, Presentation on Clinical Trials, symptomatic therapies and diagnostic approach to PSP, MSA, CBD, LBD disorders, Dr. Schiess and Dr. Allison Boyle at Memorial Hermann Southwest Learning Center, 1-21-2017 1:00 to 3:00 pm.



- 02/2018 “REM Sleep Behavior Disorder...more than a parasomnia” invited seminar for University of Texas Medical Branch at Galveston; Neuroscience Seminar Series.
- 03/2018 “Pre-symptomatic to Asymptomatic: investigations into halting the progression of Parkinson’s disease” Mya Schiess, MD invited Seminar Speaker for the University of Texas at San Antonio, Perry and Ruby Stevens Foundation in support of the Center of Excellence in Parkinson’s Disease.
- 05/2018. “New Approaches for Transforming the Course of Parkinson’s disease”. Moderator and Program Director Mya Schiess, MD, May 12<sup>th</sup>, 2018 UTHealth Neuroscience Research Center Public Forum.

---

**N ation al:**

**PRESENTATIONS/  
INVITED LECTURES  
OR SEMINARS**

- 02/2002 Management and Control over Refractory Seizures in MR/DD Population. 31st Annual APDDA conference. New Orleans, LA.
- 03/2004 Intrathecal Baclofen Pumps in the Treatment of Spasticity  
Nationally Televised Lecture Series to over 90 affiliated TV stations  
Medstar- Healthcare Network. February thru March.
- 10/2004 ITB Therapy for the Adult Neurologist Faculty  
Cleveland Clinic, Cleveland, Ohio
- 06/2005 Spasticity Management Medtronic sponsored workshop, Cleveland, Oh
- 01/ 2006 Spasticity Management in the Patient with Stroke or MS; the role of ITB therapy. Spasticity: Pathophysiology and Diagnosis in the Context of Other Movement Disorders. Intrathecal Baclofen Screening Trial in the Stroke Patient. DBS Therapy in Movement Disorders. Patient Selection for ITB Therapy in the Stroke Population. San Francisco, CA
- 10/2007 Spasticity Management- ITB therapy in Post Stroke Hemiplegia ITB Therapy in Adult Spasticity; Dosing Guidelines for ITB therapy  
Functional Improvement in Upper Extremity with ITB Therapy  
Denver, Colorado
- 11/2008 Invited Speaker New York Medical College at Westchester, NY  
Neurology & Neurosurgery Grand Rounds CME approved Intrathecal Baclofen Therapy for Post Stoke Spastic Hemiparesis, Westchester, NY
- 10/2009 National Neurology Residency Teaching Conference- Common Movement Disorders, Parkinson’s disease, tremor, dystonia; Spasticity; Therapies – DBS, ITB, Botulinum toxin. Chicago, Il.
- 10/ 2009 National Spasticity Management- Adult and Pediatric, Neurology and PM&R  
Advanced ITB therapy and Rehab, Washington, DC
- 10/2009 University of Arkansas Visiting Professor, Parkinsonian Degeneration: a Neuroinflammatory Process, UAMS, Little Rock, AK
- 05/2010 Parkinson’s Disease Biomarker Strategic Planning Workshop  
Cross-Sectional Study of Patterns in Early PD, NIH, NINDS, Georgetown, DC

08/2010	National Ataxia Foundation Seminar on Ataxias, Update on diagnosis, therapies and research Speaker: Mya Schiess, MD, Brian Aalbers, DO
10/2010	National Neurology Residency Symposium on Movement Disorders, ITB functional outcome in Spastic Hemiparesis, Common Movement Disorders; DBS Selection and Programming. Chicago, IL
02/2011	Deep Brain Stimulation- Fellows Seminar- Practices and Practice DBS Therapy: Clinical Review of Patient Selection, Surgical and Practice Management, Post DBS Medical Management, Advanced DBS therapy and Practice Guidelines. San Francisco, CA
06/2012	Resting State Brain Networks: Human Brain Mapping International Conference, Beijing, China June 2012
07/2014	Keynote Speaker for the 3 <sup>rd</sup> Annual Pennington Research Conference in Baton Rouge, Louisiana. "Inflammatory Process in Parkinson's Degeneration." Associated with LSU Medical School.
05/2018	Moderator for Neuroscience Research Center Public Forum, "New Approaches for Transforming the Course of Parkinson's Disease", Expert panelists, Q&A.
02/2018	"REM Sleep Behavior Disorder: a prodromal alpha-synucleinopathy" Grand Rounds at UTMB, Department of Neurology, Galveston, Texas
03/2018	"Pre-symptomatic to Asymptomatic: Investigations into Halting the progression of Parkinson's Disease" Invited Research Seminar for the Perry and Ruby Stevens Parkinson's Center of Excellence at UTHSCSA, Institute for the Integration of Medicine and Science, San Antonio, Texas

**CLINICAL AND  
SERVICE  
RESPONSIBILITIES**

<u>1995- 2005</u>	Neurology Consultant at Richmond State School (RSS) MHMR, Richmond, Texas  Two Neurology Clinics per month and On Call to RSS for consultation  Admit to UTHMS Hermann Hospital several RSS cases per month for tertiary care. Provided vagal Nerve Stimulation placement in collaboration with neurosurgery for intractable epilepsy patients and ITB for intractable spasticity.
<u>1999- Pre sent</u>	Neurology Ward Inpatient and Consult Attending at Memorial Hermann Hospital  Service time 8- 12 weeks per year
<u>1999- Pre sent</u>	Clinics by Specialty (UTMOVE)- University of Texas physicians  Service time 5 half-days a week
<u>2000- Pre sent</u>	Neurology Consult Attending at TIRR  Service time 8 weeks per year
<u>2000- 2014</u>	Neurology Consult Attending at LBJ HCHD Hospital  Service time 4-12weeks per year
<u>2014- 2016</u>	CALL SCHEDULE: Created the Faculty Call Schedule for Attending Coverage of general Neurology Inpatient wards and Consult services at Memorial Hermann Hospital, TIRR and LBJ HCHD. Developed split call coverage to maximize coverage and clinical services.

**RESEARCH BASIC  
SCIENCE/CLINICAL  
RESEARCH  
RESPONSIBILITIES**

**Past Laboratory Research UTMB :**

- Analysis of Central Dopamine and Serotonin electrophysiology and pharmacology with electrophysiological and morphological typing of amygdala neurons.
- The neurobiological substrate and pathophysiology underlying schizophrenia;
- The mechanism of action at the neuronal membrane level of the antipsychotic drugs;
- The effects on signal transduction in animal models of psychiatric diseases and neuroleptics.
- Investigation of the amygdala's functional interaction with the extrapyramidal system, motor cortex, and brainstem as these relate to neurodegenerative diseases; such as Parkinson disease.
- The role of serotonin at the level of the amygdala in influencing VTA and Substantia nigra dopamine transmission.
- The role of serotonin in movement disorders.
- The role of amino acids and specifically Glycine, Glutamate, and GABA in the pathophysiology of Parkinson's disease.
- The activity of glutamate and glycine at the NMDA receptor at the level of the subthalamic nucleus and globus pallidus internus.

*Laboratory Methods:*

Electrophysiology Methods (includes): in vivo animal preparation, current clamp and voltage clamp recording, extracellular single unit recording, synaptic stimulation and potential recording, microiontophoresis; in vitro slice preparation, intracellular single unit recording.

Histology/Morphology/ Neuronal Cell Labeling and Staining.

Chronic Drug Treatment Protocols.

Treated Animal Behavioral Rating Protocols.

High-Pressure Liquid Chromatography of 5-HT, HVA, 5-HIAA, DA, DOPAC, 5-HTP, Tryptophan, NE, Amino Acids in ventricular CSF of Movement Disorder patients and Neurological controls.

Extracellular single unit and multi-unit microelectrode recording of neuronal activity from striatal and pallidal neurons intraoperatively during posteroventral pallidotomy procedures.

Cell Cultures; CSF antibody, ELISA; DNA gel laddering analysis

**CURRENT CLINICAL/TRANSLATIONAL RESEARCH :**

- Creating a classification criteria and validation of classification criteria for the tremor dominant, mixed and akinetic-rigid subtypes of Parkinson's disease.
- Correlating the differences in transmitter profiles as determined by HPLC analysis of ventricular cerebrospinal fluid between the subtypes and the expression of specific disease symptomatology.
- Cell Culture and animal models for understanding the pathophysiology of Parkinson's disease; lipopolysaccharide bacterial endotoxin exposure as an animal model for Parkinson's disease.
- Clinical trials in modifying the rate of progression within the akinetic-rigid versus tremor dominant subtypes of Parkinson's disease by addressing the biochemical differences between the subtypes.

- Clinical trials in identifying the premotor or presymptomatic biomarkers for idiopathic Parkinson's disease (iPD). Identifying the biomarker(s) that have the highest predictive value in discriminating between iPD, Lewy body dementia (LBD) and Multiple System Atrophy (MSA) in the high-risk subclinical REM sleep behavior patient population.
- Putamen Volumes in iRBD.
- Assessing non-invasive methods that can reliably predict the development of iPD vs. LBD vs. MSA.
- Role of phosphorylated  $\alpha$ -Synuclein in Parkinson disease.
- Assessing the clinical effect and neuropathological effect of lithium carbonate on individuals with Spinocerebellar Ataxia Type 1.
- Neuroimaging and CSF/Serum analysis in REM Sleep Behavior Disorder to Identify Pre-Motor Biomarkers for the Initial Stages of Parkinson's Disease
- Rest State Nigrostriatal Functional Connectivity in RBD.
- Longitudinal Biomarker study emphasizing the natural history of REM Sleep Behavior Disorder as prognostic for PD- identifying the peripheral immune response in RBD, PD, MSA, and control. The current emphasis on immune profiling and correlation to disease and progression with phenotyping.
- Developing protocols for autologous and healthy adult allogeneic mesenchymal cell therapies for the treatment of Parkinsonian degenerative diseases for IND approval and subsequently developing clinical trial protocols for therapy in PD, MSA, and other Parkinsonian degenerative disorders.
- Devices interaction as a disease progression marker for Parkinson's disease.

### Medical Research Grants

<b>CURRENT FUNDED RESEARCH</b>	2008-Present	Biomarkers for Parkinson's disease: Early Detection and Neuroprotective Therapies. Funded by Kanaly Family Fund for Parkinson Disease Research PI: Mya Schiess, MD. DC \$ 130,000
	2011-2022	A Natural History Analysis of Rapid Eye Movement Sleep Behavior Disorder as prognostic for Parkinson's Disease. Funded by Adriana Blood Endowed Research Chair In Neurology. PI: Mya Schiess, MD HSC-MS-08-0147; NCT 00817726
	2012-Present	Recharge Performance Study for DBS, Sponsor Medtronic Inc. HSC-MS-06-0246. PI: Mya Schiess, MD
	2012-Present	ISPR Implantable System Performance Registry for DBS, Medtronic, Inc. PI Mya Schiess, MD
	2014-2018	STEADY-PD III, Multicenter study on the Effectiveness of Isradipine on Early PD. PSG and NIH Sponsored study. NCT02168842. PI: Mya Schiess, MD.
	2014-2018	National Device Product Surveillance Registry for DBS, ITB, and Neural Stimulators. Sponsor Medtronic Inc. HSC-MS-13-0498. PI: Mya Schiess, MD
	2015- 2019	Allogeneic Stem Cell therapy for Neurodegenerative Diseases, PI Mya Schiess Philanthropic Support \$965,100. Development and execution of pilot clinical trials using allogeneic stem cells for the treatment of typical idiopathic PD and

	atypical PD, specifically multiple system atrophy; support for any research that adds to the understanding of the role of neuroinflammation in Parkinsonian degeneration. FDA/IND # 16756 Pilot Phase I Study of Allogeneic Bone marrow-derived Mesenchymal Stem cell therapy for idiopathic Parkinson's disease. NCT02611167
2015-2019	Statistical methods for clinical trials with multivariate longitudinal outcomes CFDA: 93.853 OC: 414A PCC: GILBPCR Grant Number: 1 R01 NS091307-01A1. Principal Investigator: Sheng Luo, Ph.D. Clinical Co-Investigator: Clinical: Mya Schiess, MD
2016-2020	SURE-PD, Study of Urate Elevation in Parkinson's Disease, phase 3, PSG and NIH Sponsored study. NCT02642393. PI: Mya Schiess, MD
2017-Pending	Parkinson's Disease and Gut Microbiome PROJECT "A Prospective, Randomized Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects with Parkinson's Disease, Study Number UT-SPH/KRF FMT-2016-PD-01; Investigational Product: PRIM-DJ2727 (Microbiota Suspension) PI: Dr. Herbert Dupont, Co-Investigator: Dr. Mya Schiess; Philanthropically supported.

#### **Ed u c a t i o n a l G r a n t s :**

2002-2005	Masters Teacher Award "Teaching Residents to Teach", Mya Schiess, M.D. UTHMS Sponsored Educational Award DC \$10,000
2004-2005	Educational Grant to support Movement Disorder Research Fellow. Awarded by Medtronic, Inc. Movement Disorders Fellow DC \$12,500
2005-2006	Educational Grant to support Movement Disorder Research Fellow Training in Indication, Patient Selection, Programming for Deep Brain Stimulation. Awarded by Medtronic, Inc. DC \$25,000
2005-2006	TEVA sponsored Educational Support Grant for the Department of Neurology Residents. DC \$10,000
2005-2006	Educational Grant for the support of Department of Neurology Resident Training: Allergan Botulinum Toxin Type A sponsored by the Neuroscience Division. DC \$20,000
2006-Present	Educational Grant to support Movement Disorder Research Fellow Training in Indication, Patient Selection, Programming for Deep Brain Stimulation. Awarded by Medtronic, Inc. \$25,000 grant per year designated to support Movement Disorders Fellow's Education; total DC over 10 years \$250,000.
2012-2016	XCiDaBLE, Prospective, observational trial evaluating Xeomin® (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States; HSC-MS-11-0255, PI: Erin Furr Stimming, MD, Co-I Mya Schiess, MD
2013-2016	Deep Brain Stimulation Induced Neural Plasticity in Parkinson's Disease, HSC-MS-09-0648 PI: Al Fenoy, MD; Co-I Mya Schiess, MD

**PAST GRANT  
SUPPORT:**

- 1984-1990 National Institutes of Child Health and Human Development: Physician Scientist Award, The Electrophysiology of the Sexually Dimorphic Nucleus of the Medial Pre-optic Area of the Rat. PI Mya Schiess, MD. ID/DC \$1,200,000
- 1989-1991 Scottish Rite Schizophrenia Research Program, Intracellular Electrophysiological Analysis of Chronic Neuroleptic Treatment at the Central Nucleus of the Amygdala, Principal Investigator: Mya Schiess, MD. DC \$80,000
- 1992-1994 The Effects of Agricultural Pesticides on the GABA/BZD Receptor of the Mammalian Central Nervous System. Sponsored Research Project with the University of Texas Health Science Center at Houston. Co-Investigator- Mya Schiess, MD. DC \$16,000
- 1994-1995 Serotonergic Neuromodulation of Electrophysiologically and Morphologically Defined Cells in the Central Nucleus of the Amygdala. Pearl and Aaron Forman Research Foundation, UTMB Small Grant. PI: Mya Schiess MD.DC \$12,500.
- 1994-1995 Analysis of Effects of Atypical Antipsychotics on Amygdala Membrane Physiology. Pfizer Inc, Research, and Education Grant, PI-Mya Schiess, MD. DC \$4,800.
- 1996-1997 Unilateral Posteroventral Pallidotomy: Prospective Analysis of the Cognitive Sequelae. Source: Houston Area Parkinson's Society (HAPS). Soukup VM, Ingram F, Schiess, MC, Bonnen JC, Nauta HJW, Calverley JR. DC \$ 20,000
- 2000-2001 Preliminary Data on MEG and Neuropathic Pain, Dementia and Depression. Sponsor 4-D Imaging. PI: Andrew Papanicolaou, Ph.D.; Clinical Co-investigator: Mya C. Schiess, MD. DC \$15,000
- 2002-2007 Attention and Eye Movements in Parkinson's Disease. National Institutes of Neurological Disease and Stroke. PI Anne Sereno, Ph.D.; Co-I Mya C. Schiess, MD.
- 2002-2007 Evaluation of the Effectiveness of Subthalamic Deep Brain Stimulation and Its Effect on Neuropsychological Function in the Treatment of Medically Intractable Parkinson's Disease. Sponsored by Houston Area Parkinson's Society PI: Gage Van Horn, MD, Co-I: Mya Schiess, MD
- 2003-2009 Assessment of Quality of Life for Spastic Hemiplegic Stroke after Intrathecal Baclofen Pump Placement. Funded by Medtronic Incorporated. PI: Mya Schiess, MD DC \$230,000
- 2005-2008 Evaluation of the Efficacy and Safety of ALTROPANE for Differentiating Parkinsonian Syndromes from Non-Parkinsonian Syndromes in Patients with Tremors. Boston Life Sciences, Inc. PI: Mya Schiess, MD DC \$115,000
- 2005-2008 Adagio Clinical Study Protocol - A multicenter, Double-Blind, Randomized Start, Placebo-Controlled Study To Assess Rasagiline As A Disease Modifying Therapy In Early Parkinson's Disease Subjects. Teva Pharmaceutical Industries Ltd. PI: Mya Schiess, M.D. DC \$185,000
- 2005-2008 The Role of Cytokines and Chronic Inflammation in the Pathogenesis of

	Parkinson Disease. Funded by Kanaly Fund for Parkinson Disease Research. PI Mya Schiess, MD. DC \$ 75,000
2006-2008	PramiBID: A randomized, double-blind, active (pramipexole 0.75 mg TID) and placebo-controlled efficacy study of pramipexole, given 0.5 mg and 0.75 mg BID over a 12-week treatment phase in early Parkinson's disease patients. PI: Mya C. Schiess. DC \$65,000
2008-2009	AIM study- 123 I-ALTROPANE® Reference Image Acquisition in Subjects with Diagnostically Uncertain Tremor. Alseres Sponsored PI Mya Schiess, MD
2008-2009	An 8-week, prospective, randomized, double-blind, double-dummy, active-controlled, multi-center comparison study of the effects of Stalevo® versus immediate-release carbidopa/levodopa on non-motor symptoms in patients with idiopathic Parkinson's disease and demonstrating non-motor symptoms of wearing off. NOVARTIS. PI: Mya Schiess, MD
2008-2011	Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD; Early PD Biomarkers. Funded by Adriana Blood Endowed Chair in Neurology Research Fund. PI: Mya Schiess, MD
2009-2013	Imaging, CSF, Cognitive and Behavioral Biomarkers in Multiple System Atrophy. Funded by the Ann Vande Vanter Research Foundation For MSA. PI: Mya Schiess, MD
2011- 2013	An Open-label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study. Sponsor TEVA. PI: Mya Schiess, MD
2014-2015	Coupling of brain magneto-electrical (MEG) activity with metabolic activity: an innovation in the era of hybrid imaging. HSC-MS-14-0854. PI: Dr. Isis Gayed, Co-I: Mya Schiess, MD
2014-2016	Recruit – Minority Recruitment in Steady PD III. A Randomized Recruitment intervention Trial Developed with UT School of Public Health. PI: Mya Schiess, MD
2012-2016	Deep Brain Stimulation effects on Speech in Parkinson's disease DBS Speech Analysis in PD, HSC-MS- 10-0075. PI: Al Fenoy, MD; Co-PI Mya Schiess, MD

#### ABSTRACTS:

#### PUBLICATIONS AND PRESENTATIONS

1. **Schiess MC**, Dudley CA, Moss RL. Estrogen Priming Affects LHRH Sensitivity but No Beta Endorphin Sensitivity at the Midbrain Central Grey. Soc. Neuroscience Vol. 15; 285.5,1985.
2. **Schiess MC**, Jöels M and Shinnick-Gallagher P. Estrogen Priming Affected Medial Amygdala Neuron Excitability Recorded Intracellularly. Soc. Neuroscience, Vol. 13; 306.5, 1987.
3. **Schiess MC**, Jöels M. and Shinnick-Gallagher P. The Effects of Dopamine on Central Amygdala Neurons, in vitro Intracellular Recording. Soc. Neuroscience, vol. 18; 377.10, 1988.

4. **Schiess MC** and Shinnick-Gallaghe P. D1 and D2 Dopamine Receptor Agonists decrease Inwardly Rectifying Currents in the Central Nucleus of the Rat Amygdala. Soc. Neuroscience, Vol. 19, Oct. 1989.
5. **Schiess MC**. Chronic Haloperidol and Clozapine Treatment at the Central Nucleus of the Rat Amygdala. Soc. Neuroscience, 575.4, 1991.
6. **Schiess MC**. Acute Clozapine Treatment Alters Active Membrane Properties at the Amygdala Central Nucleus. Soc. Neuroscience, Vol. 19, 158.5, 1993.
7. Zheng H, Lakoski JM and **Schiess MC**. Serotonin Modulates Synaptic Transmission and Active Membrane Properties in the Amygdala Central Nucleus. Soc. Neuroscience, Vol. 19, 305.6, 1993.
8. Zheng H and **Schiess MC**. Correlation of Electrophysiology and Morphology of Central Amygdala Neurons, Using Neurobiotin Intracellular Recordings. 7th Annual Sigma Chi Research Forum. February 9, 1995, UTMB, Galveston.
9. James-Hewitt E. and **Schiess MC**. Frequent Intermittent Boluses of IV Lidocaine Cause CNS Toxicity. American Academy of Neurology Annual Meeting #P0756, May 1995, Seattle, WA.
10. **Schiess MC**. Atypical Neuroleptics, Clozapine and Olanzapine, have different effects on Central Amygdala Membrane Properties and Synaptic Potentials, presented as Abstract and Poster in IBC Conference, Schizophrenia. Philadelphia, PA. May 8-9, 1995.
11. Zheng H and **Schiess MC**. Serotonin Modulates Synaptic Transmission at the Central Amygdala Nucleus accepted # 05420, Society for Neuroscience, 1995.
12. **Schiess MC**. and Zheng H: Intracellular Recordings from Neurobiotin Stained Neurons of the Central Amygdala Nucleus #11240, Society for Neuroscience, 1995.
13. Zheng H, **Schiess MC**, Nauta HJ, Bonnen JG. Concentrations of Free Dopamine, Serotonin, Norepinephrine and their Metabolites in Ventricular CSF of Parkinson's disease Patients, Society for Neuroscience, 1996.
14. Soukup V, Ingram F, **Schiess MC**, Bonnen G, Calverley J, Nauta H. Cognitive Sequelae of Posteroventral Pallidotomy, National Academy of Neuropsychology, 1996.
15. Soukup VM, Ingram F, **Schiess MC**, Bonnen JG, Nauta HJW, and Calverley JR. Cognitive Sequelae of Posteroventral Pallidotomy. Archives of Clinical Neuropsychology. 1997
16. **Schiess MC**, Zheng H, Bonnen JG, Soukup VM, Calverley JR, Nauta H.J. Concentrations of Amino Acids in Ventricular CSF of Parkinson's Disease Patients, Society for Neuroscience, 1997.
17. Bonnen JG, **Schiess MC**, Zheng H, Soukup VM, Calverley JR, Nauta HJ: Imaging-Intensive Posteroventral Pallidotomy: Technique and Results, Congress of Neurosurgery, 1997.
18. Bonnen JG, **Schiess MC**, Zheng H, Soukup VM, Calverley JR, Nauta HJ. Amino Acids in Ventricular CSF of Parkinson's Disease Patients, Congress of Neurosurgery, 1997.
19. Hollingsworth CL, Chaljub G, **Schiess MC**, Bonnen G, Nauta HJ, Mandava P. MR Imaging-Guided Microelectrode Ablation of Posteroventral Pallidotomy for refractory Parkinson's Disease, 83rd Annual Meeting of the Radiological Society of North America, 1997.
20. Nauta HJ; Bonnen JG; Soukup VM, Gonzalez A, **Schiess MC**. Imaging-intensive guidance with confirmatory physiological mapping for neurosurgery of movement disorders. Proc. SPIE 3262, Surgical-Assist Systems, 253. June 5, 1998. San Jose, CA
21. **Schiess MC**, Zheng H, Bonnen JG, Nauta HJ, Soukup V.M.: Correlation of Ventricular concentration of 5-hydroxy indole acetic acid (5-HIAA) and glycine to dominate symptomatology in Parkinson's disease. October 12, 1998; 5th International Congress of Parkinson's disease and Movement Disorders, New York, NY.



22. Edwards K, **Schiess MC**, Vickery B, Dollar L, McKenzie D. VGPRO101- Study Group Rational Polytherapy with Sabril (Vigabatrin) versus Carbamazepine or Phenytoin Monotherapy in the Management of Patients with Complex Partial seizures American Epilepsy Society, 1998.
23. Cain AE, Amador SC, Alrefai A, **Schiess MC**. and Sereno, A.B.: Medications Increase Reflexive Saccade Latencies in Parkinson's disease Patients, Society for Neuroscience, 2002.
24. Cain A, Amador S, Briand K, Alrefai A, **Schiess MC**, Sereno A. Medications Reduce Errors in Antisaccade Tasks in Parkinson's Disease Patients, Movement Disorder's International Symposium. Florida, USA. November-2002.
25. Izor R, Fisher S, Simpson R, Johnson K, Tran T, and **Schiess MC**: Intrathecal Baclofen Pump Therapy Improves Functional Motor Control and Quality of Life in Spastic Hemiplegia After Stroke, International Movement Disorders Society,. Rome, Italy. June 2004.
26. Jagar AA, Amador SC, **Schiess MC**, Sereno AB. Dopaminergic Medication and Cognition in Parkinson's disease. Presented at the Society for Neuroscience 35th Annual Meeting, Washington, DC. , November 2005.
27. **Schiess MC**, Fisher S, Izor R, Furr E, Simpson R, Van Horn G. Significant Tremor Control after STN-DBS in Tremor –Dominant Idiopathic Parkinson Disease # 950274. 58th Annual Meeting of the American Academy of Neurology. San Diego, CA. April 2006.
28. **Schiess MC**, Furr E, Kaur B, Oh I, Poindexter B, Kott M-L, Bick D, Doursout M-F, Bick R. Cytokine Effects on Parkinson Associated Proteins,  $\alpha$ -synuclein, Tau and Ubiquitin in Cultured Glial Cells: Localization and Densities by Deconvolution Fluorescence Microscopy, AAN. Boston, MA. April 2007.
29. Mann M, Poindexter B, **Schiess M**, Bick R. Calcium Movements in CGRP-treated, cultured skeletal muscles, examined by real-time and deconvolution fluorescence microscopy: a role for the peptide in tension headaches. 2007 Summer Research Program for Medical Students; UTHMS Research Forum, October 2007.
30. Hood AJ, **Schiess MC**, Sereno AB. Exogenous and endogenous covert orienting of attention in Parkinson's disease. 37th Annual Society for Neuroscience. San Diego, CA. Poster 634.1. November 2007.
31. **Schiess MC**, Poindexter B, Hook D, Doursout M-F, Bick R. Localization and density of PD associated proteins and cytokines after lipopolysaccharide treatments. Movement Disorders Society 12th International Congress of Parkinson's Disease and Movement Disorders #12. Chicago, Illinois. June 2008.
32. Furr Stimming E, Oh IJ, Van Horn G, Simpson R, **Schiess MC**. Sensitivity and Specificity of Levodopa Response in Predicting Deep Brain Stimulation Outcomes in Parkinson's Disease. # 396; Movement Disorders Society 12th International Congress of Parkinson's Disease and Movement Disorders. Chicago, Illinois. June 2008.
33. Hood AJ, Amador SC, **Schiess MC**, Sereno AB. Medication Improves Executive Function in Tremor- Dominant Subtype of Idiopathic Parkinson's disease. # 273; Movement Disorders Society 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, Illinois. June 2008.
34. **Schiess MC**, Barnes J, Poindexter B, Oh I, Bick R. CSF from Parkinson's disease Patients Differentially Affects  $\alpha$ -Synuclein Density and Cell growth in Microglia compared to Astrocytes. Neurology, (Suppl 3). March 17, 2009.

35. **Schiess M**, Schurdell M, Gordon M, Kidder G, Poindexter B, Bick R. Animal Model of Endotoxin-Induced Neurodegeneration in Parkinson's disease. Movement Disorder Society's 13th International Congress. June 2009.
36. **Schiess M**, Barnes J, Gordon M, Poindexter B, Bick R. CSF from Parkinson's disease patients affects alpha-synuclein density and cell growth in microglia and astrocytes. Movement Disorder Society's 13th International Congress. June 2009.
37. Oh I, **Schiess MC**, Van Horn G, Furr Stimming E. The impact of Subtype and Disease Duration on Quality of Life in Parkinson's Disease, Movement Disorder Society's 13th International Congress. June 2009.
38. Madan A, **Schiess MC**. Intrathecal Baclofen Therapy Slows Progression in Multiple System Atrophy, Movement Disorder Society's 13th International Congress. June 2009.
39. Hood AJ, **Schiess MC**, Sereno AB. Adjuvant Medication Can Decrease Deep Brain Stimulation –Induced Impulsivity: A saccade study in Parkinson disease. AAN abstract for 2010.
40. Hendley K, Ellmore T, Hood AJ, Aalbers B, Furr-Stimming F, Castriotta R, **Schiess MC**. Interim Analysis of Clinical and Behavioral Measures Defining Idiopathic REM Sleep Behavior Patients at Risk for Developing a Parkinsonian Syndrome. MDS abstract, June 2011.
41. Ellmore T, Hendley K, Aalbers B, Furr-Stimming E, Hood AJ, Castriotta R, **Schiess MC**. Substantia Nigra Rest-State fMRI Correlation Differences between REM Sleep Disorder and Early PD Patients. MDS abstract, June 2011.
42. Copeland B, Ellmore T, Beurlot M, Liang Q, Suescun J, Furr-Stimming E, Castriotta R and **Schiess M**. Region of Interest Measurements of Structural Volumes in Patients with Parkinson's Disease, Atypical Parkinsonism, and REM sleep Behavior Disorder: Baseline Measurements from a Prospective Longitudinal Study. American Academy of Neurology, April 2012
43. Liang Q, Copeland B, Ellmore T, **Schiess M**. Supplemental Treatments of deficits in cerebrospinal fluid neurotransmitter levels in Spinocerebellar ataxia type 1 correlates with clinical improvement, Movement Disorders Society. June 2012.
44. Copeland B, Liang Q, Beurlot M, Ellmore T, Furr-Stimming E, Castriotta R, **Schiess M**. Correlation of olfactory function and olfactory bulb volume in REM sleep behavior disorder, Movement Disorders Society. June 2012.
45. Ellmore T, Copeland B, Beurlot M Liang Q, Suescun J, Erin Furr-Stimming E, Castriotta R, **Schiess M**. Structural volumes in patients with Parkinson's disease, atypical parkinsonism, and rapid eye movement sleep behavior disorder: baseline measurements from a prospective longitudinal study, Movement Disorders Society. June 2012.
46. **Schiess M**, Liang Q, Copeland B, Erin Furr-Stimming E, Castriotta R. Comparison of clinical and behavioral measures distinguishing and predicting Parkinsonian Syndromes in REM sleep behavior disorder patients, Movement Disorders Society. June 2012.
47. Copeland B, Liang Q, Ellmore T, Furr-Stimming E, Ephron V, **Schiess M**. Abnormal Cerebrospinal Fluid neurotransmitter profiles in a father and daughter with Spinocerebellar ataxia type 1, National Ataxia Foundation abstract. March 2012.
48. Gayed I, Joseph U, Wan D, Ondo W, **Schiess M**. DaTScan is a robust Imaging Modality for Patients with Movement Disorders, Society for Nuclear Medicine. May 2012.
49. Smith L, **Schiess M**, Coffey M, Klaver A, Loeffler D. Comparison of serum alpha-synuclein and anti-alpha-synuclein antibody concentrations in individuals with Parkinson's disease,

- atypical Parkinsonism, Rapid eye movement sleep behavior disorder and healthy subjects. Society for Neuroscience, 2012.
50. Ellmore T, Cruz K, Castriotta R, **Schiess MC**. Changes in Substantia Nigra Functional and Structural Connectivity with Motor Integrity. Human Brain Mapping. 2013.
  51. Smith KC, McGuire M, Bick D, **Schiess M**. Th-2 type Cytokines in the Plasma of Parkinson's disease Patients are Up-regulated. ANA Annual Conference. October 2013.
  52. Copeland B, Ellmore T, Fenoy A, **Schiess M**. Deep Brain Stimulation of the Globus Pallidus for Generalized Dystonia Associated with Spinocerebellar Ataxia Type I. ANA Annual Conference, October 2013.
  53. Smith KC, McGuire M, Bick D, **Schiess M**. Measurement of plasma cytokines suggests Th2 dominated T cell dysregulation in Parkinson's disease. World Parkinson's Congress, Montreal, Canada. October 2013.
  54. Guthikonda L, Red S, Wilson A, Sereno A, Patel S, Copeland B, Castriotta R, Ellmore T, **Schiess M**. Cortical and subcortical brain volumes and clinical correlates in preclinical and clinical Parkinsonism. World Parkinson's Congress. Montreal, Canada. October 2013.
  55. Red S, Copeland B, Wilson A, Guthikonda L, Ellmore T, Castriotta R, **Schiess M**, Sereno A. Using Eye Movements to Differentiate between Subclinical and Clinical Types of Parkinsonism. World Parkinson's Congress. Montreal, Canada. October 2013.
  56. Fenoy A, McHenry M, Ellmore T, **Schiess MC**. Speech Dysfluencies induced by Deep Brain Stimulation in Parkinson's Disease –a Fiber-Tract Analysis, ANA Annual Conference. October 2013.
  57. Bick DLM, Doursout MF, **Schiess, MC**, Poindexter BJ, Bick, RJ. Cellular Responses to Inflammation in the Central Nervous System: nitric oxide synthase isoform expression in cell culture and animal models. Experimental Biology. San Diego, CA. April 26-30, 2014.
  58. Moro E, Schupbach M, Wachter T, Allert N, Eleopra R, Honey C, Rueda M, **Schiess M**, Shimo Y, Valkovic P, Whone A, and Stoevelaar H. Appropriate Referrals for the Evaluation of Deep Brain Stimulation in Parkinson's disease: New Recommendations from a Worldwide Panel. Movement Disorders Society. June 2014.
  59. Ellmore T, Murphy SM, Cruz K, Castriotta RJ, and **Schiess MC**. Averaging of Direction-Encoded Color Maps for Localizing Substantia Nigra. American Neurological Association Annual Conference. October 2014.
  60. **Schiess MC**, Doursout MF, Bick DH, Liang Y, Poindexter BJ and Bick RJ. NOS Isoforms in an LPS Animal Model of Parkinson's disease. American Neurological Association Annual Conference. October 2014.
  61. **Schiess M**, Suescun J, Copeland B, Ellmore T, Furr-Stimming E, Castriotta R. Uric acid levels and disease duration in REM sleep behavior disorder and Parkinsonian syndromes. MDS, San Diego, CA. June 2015.
  62. Smith KC, Suescun J, Bick DL, **Schiess MC**. Patterns of peripheral immune activity in prodromal asymptomatic and symptomatic Parkinsonism. MDS, San Diego, CA. June 2015.
  63. Reddy ST, Fenoy AJ, Furr-Stimming E, Ondo WG, **Schiess MC**, Mehanna R. Does the use of intraoperative microelectrode recording influence the final location of lead implant in the ventral intermediate nucleus for deep brain stimulation? MDS, San Diego, CA. June 2015.
  64. Reddy ST, Fenoy AJ, Furr-Stimming E, Ondo WG, **Schiess MC**, Mehanna R. Does the use of intraoperative microelectrode recording influence the final location of lead implant in the sub-thalamic nucleus for deep brain stimulation? MDS, San Diego, CA. June 2015.

65. Reddy ST, Fenoy AJ, Furr-Stimming E, Ondo WG, **Schiess MC**, Mehanna R. Intraoperative microstimulation predicts the outcome of postoperative macro stimulation in STN DBS for PD. MDS, San Diego, CA. June 2015.
66. Ellmore T, Castriotta R, Suescun J, **Schiess M**. Negative functional connectivity between substantia nigra and hippocampus in REM sleep behavior disorder. *Sleep Medicine* 2015; 16: S12-S13.
67. Gonzalez A, Actor A, Smith K, Suescun J, **Schiess M**. Serum Brain-Derived Neurotrophic Factor as an Indication of Disease State in Parkinsonism and REM Sleep Behavior Disorder, Neuroscience Research Conference, UTHealth, Houston, TX. October 2015.
68. **Schiess M**, Tonder L, Wells M, Weaver T, Stoker V. Real-World safety of Deep Brain Stimulation in Patients with <7.5 years between Disease Onset and Device Implant. 20<sup>th</sup> International MDS Conference, Berlin, Germany. June 20<sup>th</sup>, 2016.
69. Suescun J, Csencsits-Smith K, Actor A, Gonzalez A, Bick D, **Schiess M**. Leukocyte Perturbations Suggest Immune Dysregulation in Progressive Supranuclear Palsy: A Twin Comparison. 20th International MDS Conference, Berlin, Germany; June 20th, 2016.
70. Csencsits-Smith K, Suescun J, Wright R, Actor A, Gonzalez A, Bick D, **Schiess M**. Do serum BDNF levels reflect progression towards symptomatic alpha-synucleinopathies in patients with RBD? The Lancet Neurology Conference. Preclinical neurodegenerative disease: towards prevention and early diagnosis. October 19–21, 2016, London, UK.
71. Falowski S, Konrad, P, **Schiess M**, Johnson G, Weaver T. Performance of Deep Brain Stimulation Systems in a Real World Population. Neuromodulation: From Frontier to Frontline, NANS, Las Vegas, NV January 2017.
72. **Schiess MC**, et al. Health-related QoL as measured by the EQ-5D-5L in PD patients after DBS therapy: Preliminary results from the Product Surveillance Registry. MDS, Vancouver, BC June 2017
73. **Schiess MC**, et al. Safety of Unilateral and Bilateral DBS implants in ET: Preliminary results from Product Surveillance Registry. MDS, Vancouver, BC June 2017
74. Chandra S, **Schiess MC**, Fenoy A. Improved Atypical Tremor Control After DBS Directly Targeting the Dentato-Rubro-Thalamic Tract, ANA, San Diego October 15-17, 2017.
75. Fenoy A and **Schiess MC**. Outcomes of Directly Targeting the Cerebellothalamic Tract vs. Indirectly Targeting the VIM for ET. NANS 21st Annual Meeting Las Vegas, NV January 11-15, 2018.
76. Suescun J, Csencsits-Smith K, Chandra S, Gao Q, Miao H, **Schiess MC**. Patients with Alpha-synucleinopathies Display Distinct Chemokine Profiles. American Academy of Neurology, April 21-27, 2018 in Los Angeles, CA.
77. Suescun J, Giancardo L, Ellmore T, Ocasio L, Kamalid A, Riascos-Castaneda R, and **Schiess MC**. Longitudinal connectome-base biomarker from Diffusion Tensor Imaging for REM Sleep Behavior Disorder. American Academy of Neurology, April 21-27, 2018 in Los Angeles, CA
78. **Schiess MC**, Suescun J, Ellmore T. Preliminary evidence for an altered relationship between uric acid levels and resting state functional connectivity in REM sleep behavior disorder American Academy of Neurology 70th Annual Meeting, April 21 to April 27, 2018, in Los Angeles, CA.
79. Chandra S, **Schiess MC**, Suescun J, Fenoy A. Improved Atypical Tremor Control After Deep Brain Stimulation Targeting The Dentato-Rubro-Thalamic Tract. American Academy of Neurology, April 21-27, 2018 in Los Angeles, CA.

---

**REFEREED ORIGINAL ARTICLES:**

**PUBLICATIONS  
AND  
PRESENTATIONS**

1. **Schiess MC**, Dudley CA, Moss RL. Estrogen priming affects the sensitivity of midbrain central gray neurons to microiontophoretically applied LHRH but not beta-endorphin. *Neuroendocrinology*. 1987 Jun;46(1):24-31.
2. **Schiess MC**, Joëls M, Shinnick-Gallagher P. Estrogen priming affects active membrane properties of medial amygdala neurons. *Brain Res*. 1988 Feb 9;440(2):380-5.
3. **Schiess MC**, Asprodini EK, Rainnie DG, Shinnick-Gallagher P. The central nucleus of the rat amygdala: in vitro intracellular recordings. *Brain Res*. 1993 Feb 26;604(1-2):283-97.
4. Soukup VM, Ingram F, **Schiess MC**, Bonnen JG, Nauta HJ, Calverley JR. Cognitive sequelae of unilateral posteroventral pallidotomy. *Arch Neurol*. 1997 Aug;54(8):947-50.
5. Soukup VM, Ingram F, Grady JJ, **Schiess MC**. Trail Making Test: issues in normative data selection. *Appl Neuropsychol*. 1998;5(2):65-73.
6. Soukup VM, Bimbela A, **Schiess MC**. Recognition Memory for Faces: Reliability and Validity of the Warrington Recognition Memory Test (RMT) in a Neurological Sample. *Journal of Clinical Psychology in Medical Settings*. 1999 September; 6(3):287-293.
7. **Schiess MC**, Callahan PM, Zheng H. Characterization of the electrophysiological and morphological properties of rat central amygdala neurons in vitro. *J Neurosci Res*. 1999 Dec 1;58(5):663-73.
8. Van Horn G, **Schiess MC**. Pallidotomy: Refining the technique. *Lancet Neurology Network*. 2000; 4(1):1-3.
9. **Schiess MC**, Zheng H, Soukup VM, Bonnen JG, Nauta HJ. Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. *Parkinsonism Relat Disord*. 2000 Apr 1;6(2):69-76.
10. **Schiess M**. Nonsteroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away? *Arch Neurol*. 2003 Aug;60(8):1043-4.
11. Bick RJ, Poindexter BJ, **Schiess MC**. Localization of calcitonin gene-related peptide in cardiomyocytes: comparison of neonatal and dedifferentiating cells to adult myocytes. *Peptides*. 2005 Feb;26(2):331-6.
12. **Schiess MC**, Poindexter BJ, Brown BS, Bick RJ. The effects of CGRP on calcium transients of dedifferentiating cultured adult rat cardiomyocytes compared to non-cultured adult cardiomyocytes: possible protective and deleterious results in cardiac function. *Peptides*. 2005 Mar;26(3):525-30.
13. Bick RJ, Poindexter BJ, Davis RA, **Schiess MC**. Determination of the site of action of calcitonin gene-related peptide in the alteration of intracellular calcium levels in adult and neonatal rodent myocytes. *Peptides*. 2005 Nov;26(11):2231-8. PubMed PMID: 15979760.
14. Amador SC, Hood AJ, **Schiess MC**, Izor R, Sereno AB. Dissociating cognitive deficits involved in voluntary eye movement dysfunctions in Parkinson's disease patients. *Neuropsychologia*. 2006;44(8):1475-82.
15. Francisco GE, Yablon SA, **Schiess MC**, Wiggs L, Cavalier S, Grissom S. Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. *Top Stroke Rehabil*. 2006 Fall;13(4):74-85.
16. Van Horn G, **Schiess MC**. Benign tremulous parkinsonism? *Arch Neurol*. 2006 Oct;63(10):1507.

17. Hood AJ, Amador SC, Cain AE, Briand KA, Al-Refai AH, **Schiess MC**, Sereno AB. Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2007 Jun;78(6):565-70.
18. Hallevi H, Oh IJ, Valdez SR, Kidder BG, **Schiess MC**. Postencephalitic hemiparkinsonism: clinical imaging correlation. *Arch Neurol*. 2008 Jun;65(6):837.
19. **Schiess M**, Oh I. Serum uric acid and clinical progression in Parkinson disease: a potential biomarker for nigrostriatal failure. *Arch Neurol*. 2008 Jun;65(6):698-9.
20. Bick RJ, Mann M, Poindexter B, **Schiess MC**. Calcium Movements in CGRP-treated Cultured Skeletal Muscle Cells: Is There a Role for CGRP in Tension Headaches?. *International Journal of Peptide Research and Therapeutics*. 2008 June; 14(2):193-199.
21. Bick RJ, Poindexter BJ, Kott MM, Liang YA, Dinh K, Kaur B, Bick DL, Doursout MF, **Schiess MC**. Cytokines disrupt intracellular patterns of Parkinson's disease-associated proteins alpha-synuclein, tau, and ubiquitin in cultured glial cells. *Brain Res*. 2008 Jun 27;1217:203-12.
22. Dinh K, Poindexter BJ, Barnes JL, **Schiess MC**, Bick RJ. Fluorescence microscopy and 3D image reconstruction of cytokine initiated disruption of the Parkinson disease-associated proteins alpha-synuclein, tau, and ubiquitin in cultured glial cells. *Cytokine*. 2009 Mar;45(3):179-83.
23. Yalho TC, **Schiess MC**, Furr-Stimming E. Acute bilateral basal ganglia lesions and chorea in a diabetic-uremic patient on dialysis. *Arch Neurol*. 2010 Feb;67(2):246.
24. **Schiess MC**, Barnes JL, Ellmore TM, Poindexter BJ, Dinh K, Bick RJ. CSF from Parkinson disease patients differentially affects cultured microglia and astrocytes. *BMC Neurosci*. 2010 Nov 29;11:151.
25. Ellmore TM, Hood AJ, Castriotta RJ, Stimming EF, Bick RJ, **Schiess MC**. Reduced volume of the putamen in REM sleep behavior disorder patients. *Parkinsonism Relat Disord*. 2010 Dec;16(10):645-9
26. **Schiess MC**, Oh IJ, Stimming EF, Lucke J, Acosta F, Fisher S, Simpson RK. Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. *Neuromodulation*. 2011 Jan;14(1):38-45; discussion 45.
27. Madan A, **Schiess MC**. Intrathecal baclofen therapy slows progressive disability in multiple system atrophy. *Neuromodulation*. 2011 Mar-Apr;14(2):176-7; discussion 178.
28. Smith LM, **Schiess MC**, Coffey MP, Klaver AC, Loeffler DA.  $\alpha$ -Synuclein and anti- $\alpha$ -synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. *PLoS One*. 2012;7(12):e52285
29. Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, **Schiess MC**, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J. Phosphorylated  $\alpha$ -synuclein in Parkinson's disease. *Sci Transl Med*. 2012 Feb 15;4(121):121ra20.
30. Doursout MF, **Schiess MC**, Schurdell MS, Osuagwu U, Hook DM, Poindexter BJ, Hickson- Bick DLM, Bick RJ. Specific localization of cytokines and Parkinson's disease-associated proteins revealed by fluorescence deconvolution microscopy in brain tissue of an LPS treated rat model. *Current trends in neurology*. 2012 May; 6.
31. Doursout MF, Young LM, Vial A, Gianacakes E, Poindexter BJ, Hickson-Bick DLM, **Schiess MC**, Bick RJ. Is neurodegeneration a consequence of temporal differences in

- the induction of protective markers?. *Journal of Interferon & Cytokine Research: the official journal of the International Society for Interferon and Cytokine Research*. 2012 December
32. Copeland BJ, **Schiess MC**. Can mild cognitive impairment in Parkinson disease predict the development of dementia? *JAMA Neurol*. 2013 May;70(5):553-5.
  33. Nguyen FN, Kar JK, Zakaria A, **Schiess MC**. Isolated central nervous system histoplasmosis presenting with ischemic pontine stroke and meningitis in an immune-competent patient. *JAMA Neurol*. 2013 May;70(5):638-41.
  34. Doursout MF, Schurdell MS, Young LM, Osuagwu U, Hook DM, Poindexter BJ, **Schiess MC**, Bick DL, Bick RJ. Inflammatory cells and cytokines in the olfactory bulb of a rat model of neuroinflammation; insights into neurodegeneration? *J Interferon Cytokine Res*. 2013 Jul;33(7):376-83.
  35. Ellmore TM, Castriotta RJ, Hendley KL, Aalbers BM, Furr-Stimming E, Hood AJ, Suescun J, Beurlot MR, Hendley RT, **Schiess MC**. Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. *Sleep*. 2013 Dec 1;36(12):1885-92.
  36. Copeland BJ, Fenoy A, Ellmore TM, Liang Q, Ephron V, **Schiess M**. Deep brain stimulation of the internal globus pallidus for generalized dystonia associated with spinocerebellar ataxia type 1: a case report. *Neuromodulation*. 2014 Jun;17(4):389-92.
  37. Ellmore TM, Murphy SM, Cruz K, Castriotta RJ, **Schiess MC**. Averaging of diffusion tensor imaging direction-encoded color maps for localizing substantia nigra. *Comput Biol Med*. 2014 Aug;51:104-10.
  38. Furr-Stimming E, Boyle AM, **Schiess MC**. Spasticity and intrathecal baclofen. *Semin Neurol*. 2014 Nov;34(5):591-6.
  39. Gayed I, Joseph U, Fanous M, Wan D, **Schiess M**, Ondo W, Won KS. The impact of DaTscan in the diagnosis of Parkinson disease. *Clin Nucl Med*. 2015 May;40(5):390-3.
  40. **Schiess MC**, Suescun J. Clinical Determinants of Progression of Parkinson Disease: Predicting Prognosis by Subtype. *JAMA Neurol*. 2015 Aug;72(8):859-60.
  41. Riecke J, Johns KM, Cai C, Vahidy FS, Parsha K, Furr-Stimming E, **Schiess M**, Savitz SI. A Meta-Analysis of Mesenchymal Stem Cells in Animal Models of Parkinson's Disease. *Stem Cells Dev*. 2015 Sep 15;24(18):2082-90.
  42. Moro E, Schüpbach M, Wächter T, Allert N, Eleopra R, Honey CR, Rueda M, **Schiess MC**, Shimo Y, Valkovic P, Whone A, Stoevelaar H. Referring Parkinson's disease patients for deep brain stimulation: a RAND/UCLA appropriateness study. *J Neurol*. 2016 Jan;263(1):112-9.
  43. Suescun J, Ellmore T, **Schiess MC**. REM Sleep Behavior Disorder: a Prodromal Synucleinopathy. *Current geriatrics reports. Current Geriatrics Reports*. 2016:1-8.
  44. Reddy S, Fenoy A, Furr-Stimming E, **Schiess M**, Mehanna R. Does the Use of Intraoperative Microelectrode Recording Influence the Final Location of Lead Implants in the Ventral Intermediate Nucleus for Deep Brain Stimulation? *Cerebellum*. 2016 Aug.
  45. Doursout MF, Liang Y, **Schiess MC**, Padilla A, Poindexter BJ, Hickson-Bick DL, Bick RJ. Are Temporal Differences in GDNF and NOS Isoform Induction Contributors to Neurodegeneration? A Fluorescence Microscopy-Based Study. *Open Neurol J*. 2016 Aug 26;10:67-76

46. Fenoy AJ, McHenry MA, **Schiess MC**. Speech changes induced by deep brain stimulation of the subthalamic nucleus in Parkinson disease: involvement of the dentatorubrothalamic tract. *J Neurosurg*. 2016 Sep 9:1-11.
47. Fenoy A and **Schiess M**. Deep Brain Stimulation of the Dentato-Rubro-Thalamic tract: Outcomes of Direct Targeting for Tremor. *Neuromodulation*, DOI:10.1111/ner.12585; online January 2017.
48. Fenoy AJ, Villarreal S, **Schiess MC**. Acute and sub-acute presentations of cerebral edema following Deep Brain Stimulation lead implantation. *Stereotactic and Functional Neurosurgery* DOI:10-1159/000454892; February 2017.
49. Boyle A, Suescun J, **Schiess M**. Opicapone: A Novel Adjunct for an Old Standard. *JAMA Neurol*. 2017 Feb 1;74(2):153-154.
50. Csencsits-Smith K, Suescun J, Li K, Luo S, Bick DL, **Schiess M**. Serum Lymphocyte-Associated Cytokine Concentrations Change More Rapidly over Time in Multiple System Atrophy Compared to Parkinson Disease. *Neuroimmunomodulation*. DOI:10.1159/000460297; April 11,2017.
51. Brooks S, Klier EM, Red SD, Mehta ND, Patel SS, Chuang AZ, Suescun J, **Schiess M**, Sereno A. Slowed Prosaccades and Increased Antisaccade Errors as a Potential Behavioral Biomarker of Atypical Parkinsonism. *Multiple System Atrophy*. *Frontiers in Neurology*, June 2017.
52. Suarez-Cedeno G, Suescun J, **Schiess MC**. Earlier Intervention With Deep Brain Stimulation for Parkinson's disease. *Parkinson's disease*, August 2017.
53. Giancardo L, Ellmore T, Suescun J, Ocasio L, Kamalid A, Riascos-Castaneda R and **Schiess MC**. Longitudinal Connectome-based Predictive Modeling for REM Sleep Behavior Disorder from Structural Brain Connectivity. *Proc. SPIE 10575, Medical Imaging 2018: Computer-Aided Diagnosis*, February 2018.
54. Albert J Fenoy and Mya C Schiess. Comparison of outcomes targeting the cerebello-thalamic tract and VIM thalamus for Essential Tremor. *Movement Disorders*, In-press, 2018.

<http://www.ncbi.nlm.nih.gov/sites/myncbi/1TG2cbEuCXoQn/bibliography/49679335/public/?sort=date&direction=ascending>

#### CHAPTERS:

#### PUBLICATIONS AND PRESENTATIONS

1. Molony DA., Evanoff G, and **Schiess MC**. Respiratory Disorders: Alkalosis and Acidosis. In Fluid and Electrolyte Disorders, eds Kokko and Tannen, W.B. Saunders, 2<sup>nd</sup> edition, Philadelphia, PP 391-449, 1990.
2. Molony DA, **Schiess MC**, and Dosekun A. Respiratory Disorders; Alkalosis and Acidosis. In Fluid and Electrolyte Disorders, Eds. Kokko and Tannen, W.B. Saunders, 3<sup>rd</sup> edition, Philadelphia, pp. 267-342, 1995.
3. Francisco G, Kothari S, **Schiess MC**, and Kaldis T. Rehabilitation of Persons with Parkinson's disease and Other Movement Disorders In Rehabilitation Medicine: Principles and Practice. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2005. Pg 809-828.
4. Suescun J, Boyle A, **Schiess M**. Deep Brain Stimulation for Essential Tremor, in Deep Brain Stimulation, editors Raja Mehanna, MD, Novo press; 2015



5. Suescun J, Chandra S, **Schiess M**. The Role of Neuroinflammation in Neurodegenerative Disorders in Translational Inflammation. Elsevier. In-press 2018

#### LETTERS/COMMUNICATION:

1. Soukup VM, Ingram F, **Schiess MC**, Bonnen JG, Nauta HJW, Calverley JR. Reply to the Trepanier, Saint-Cyr, Lang and Lazano Letter, in Letters to the Editor, *Archives of Neurology*, 55, 883, 1998
2. Van Horn G, **Schiess MC**. Letter to the Editor: Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. *Neurology*. 2000 Jul 12;55(1):156-7.
3. Van Horn G, **Schiess MC**, Soukup VM. Letter to the Editor: Subthalamic deep brain stimulation: neurobehavioral concerns. *Arch Neurol*. 2001 Aug;58(8):1205-6.

#### PLATFORM PRESENTATIONS:

1. **Schiess MC**, Acosta F, Izor R, Fisher S, Furr E, Simpson R. "Functional Motor Improvement in Stroke-Related Spastic Hemiparesis after Intrathecal Baclofen Therapy" AAN, Neural Repair, San Diego, CA. April 2006.
2. **Schiess MC**, Ellmore T, Castriotta R, Bick D, Doursout MF, Stimming E, Bick R. Volumetric MRI as an Image Biomarker for the Early Diagnosis of Parkinson's Diseases. AAN Abstract for 2010.
3. Csencsits-Smith K, Suescun J, Gonzalez A, Actor A, **Schiess M**. Serum Brain-Derived Neurotrophic Factor as an Indication of Disease State in Parkinsonism and RBD. 20<sup>th</sup> International MDS Conference, Berlin, Germany; June 20<sup>th</sup>, 2016.
4. Konrad P, **Schiess M**, Stromberg K, Weaver T. Long-term Recharging Behavior and Therapy Settings in Patients Implanted with Rechargeable Deep Brain Stimulation Systems. *Neuromodulation: From Frontier to Frontline*; NANS, Las Vegas, NV, January 2017.
5. **Mya Schiess, MD**, Steven Falowski, MD, George Plotkin, MD, PhD, Stephane Palfi, MD, PhD, Thomas Witt, MD, Emmanuel Cuny, MD, Tom Theys, MD, Kenneth Martinez, MD, Robert Plunkett, MD, Yasin Temel, MD, Gayle Johnson, MPH, Todd Weaver, PhD, MPH, Joachim Krauss, MD, PhD, Peter Konrad, MD, PhD, on behalf of the PSR DBS Study Group Frequency and Characterization of Speech Problems following DBS from the Product Surveillance Registry, WSSFN, Berlin, Germany, June 26-29, 2017.
6. Albert J Fenoy and **Mya C Schiess**. Comparison of outcomes targeting the cerebellum-thalamic tract and VIM thalamus for Essential Tremor, NANS, Las Vegas, NV Jan 2018